TOPICAL ANTIOXIDANTS IN THE MANAGEMENT OF MELASMA WITH FOCUS ON SILYMARIN, VITAMIN C AND VITAMIN E

Josif Kachurov
Faculty of Medical Sciences, Goce Delchev University, Shtip, North Macedonia,
josifkachurov@gmail.com
Bistra Angelovska
Faculty of Medical Sciences, Goce Delchev University, Shtip, North Macedonia,
bistra.angelovska@ugd.edu.mk

Abstract: Melasma is a chronic acquired hyperpigmentation disorder characterized by symmetrical brown macules on sun-exposed areas of the skin, predominantly affecting women of reproductive age. Its complex pathogenesis involves genetic predisposition, ultraviolet radiation, hormonal influences and oxidative stress. Increasing evidence indicates that oxidative mechanisms play a central role in melanocyte stimulation and melanin overproduction, which has directed scientific interest toward antioxidant-based therapeutic strategies.
The purpose of this review was to summarize and critically analyze available scientific data regarding the role of topical antioxidants in the management of melasma, with particular emphasis on silymarin, vitamin C and vitamin E. A structured review of relevant scientific literature was conducted using major electronic databases, including PubMed, ScienceDirect and Google Scholar. Clinical studies, experimental research and review articles evaluating antioxidant activity, mechanisms of action, safety and clinical outcomes were included in the analysis.
The reviewed literature demonstrates that topical antioxidants exert beneficial effects in melasma primarily through inhibition of oxidative stress, reduction of reactive oxygen species and modulation of melanogenesis-related pathways. Silymarin exhibits potent antioxidant and anti-melanogenic activity, with studies reporting significant reduction in pigmentation severity and a favorable safety profile. Vitamin C contributes to depigmentation by inhibiting tyrosinase activity, reducing oxidized melanin and enhancing photoprotection, while vitamin E supports membrane stabilization and acts synergistically with other antioxidants.
Although conventional depigmenting agents remain effective, their long-term use is often limited by irritation and safety concerns. In contrast, antioxidant-based topical therapies demonstrate good tolerability and suitability for prolonged application. However, variability in formulation stability, skin penetration and study design represents an important limitation in current research.
In conclusion, available evidence supports the role of topical antioxidants as valuable components in the management of melasma. Silymarin, vitamin C and vitamin E represent promising agents, either as monotherapy or as adjuncts to conventional treatment, highlighting the need for further well-designed clinical studies and optimized topical formulations.
Keywords: melasma, antioxidants, silymarin, vitamin C, vitamin E, topical therapy

1. INTRODUCTION

Melasma is a chronic acquired hyperpigmentation disorder characterized by symmetrical brown or grayish-brown patches, most commonly affecting sun-exposed areas of the face. The condition predominantly occurs in women of reproductive age and represents a significant dermatological and psychosocial concern due to its persistent nature and frequent recurrence. Although melasma is a benign condition, its impact on quality of life is considerable, often leading to emotional distress and reduced self-esteem.
The pathogenesis of melasma is complex and multifactorial, involving genetic predisposition, ultraviolet (UV) radiation, hormonal influences, inflammatory mediators, and vascular and dermal alterations. In recent years, increasing scientific evidence has highlighted the central role of oxidative stress in the initiation and progression of melanogenesis. UV-induced generation of reactive oxygen species contributes to melanocyte stimulation, increased tyrosinase activity, and excessive melanin production.
Topical therapy remains the mainstay of melasma management. Conventional depigmenting agents, particularly hydroquinone, have long been considered effective; however, their long-term use is limited by safety concerns, skin irritation, and the risk of rebound hyperpigmentation. These limitations have prompted growing interest in safer alternatives with favorable tolerability profiles.
Antioxidants have emerged as promising candidates in the topical treatment of melasma due to their ability to neutralize reactive oxygen species, modulate melanogenic pathways, and reduce inflammatory responses. Among them, plant-derived polyphenols and classical antioxidants such as vitamin C and vitamin E have gained particular

attention. Silymarin, a flavonolignan complex extracted from *Silybum marianum*, has demonstrated potent antioxidant, anti-inflammatory, and anti-melanogenic properties in experimental and clinical studies.

The aim of this review is to summarize and critically analyze current scientific evidence regarding the role of topical antioxidants in the management of melasma, with a specific focus on silymarin, vitamin C, and vitamin E. By integrating data from clinical and experimental studies, this paper seeks to highlight their mechanisms of action, therapeutic potential, and limitations, as well as to identify directions for future research.

2. MATERIALS AND METHODS

This paper was designed as a narrative review aimed at summarizing current scientific evidence regarding the use of topical antioxidants in the management of melasma, with particular emphasis on silymarin, vitamin C, and vitamin E.

A comprehensive literature search was conducted using internationally recognized scientific databases, including PubMed, ScienceDirect, Google Scholar, and ResearchGate. The search strategy was developed to identify experimental studies, clinical trials, review articles, and relevant pharmacological reports addressing the pathophysiology of melasma, the role of oxidative stress, and the topical application of antioxidant compounds.

The following keywords and their combinations were used during the literature search: *melasma*, *oxidative stress*, *topical antioxidants*, *silymarin*, *vitamin C*, *vitamin E*, and *hyperpigmentation*. Only articles published in English were considered.

Studies were selected based on their relevance to the topic, clarity of methodology, and availability of full-text data. Priority was given to publications from the last five years; however, older studies of high scientific importance were also included to provide essential background and mechanistic insight.

Data extracted from the selected articles included information on mechanisms of action, clinical efficacy, safety profile, and limitations of topical antioxidant therapy. The collected findings were qualitatively analyzed and synthesized to provide an integrated overview of current evidence.

No experimental procedures involving human participants or laboratory testing were performed as part of this review.

3. RESULTS

Available scientific evidence indicates that melasma represents a persistent therapeutic challenge due to its chronic course, multifactorial pathogenesis, and high recurrence rate. Conventional depigmenting therapies, although effective in reducing pigmentation, are frequently associated with adverse effects and limited suitability for long-term use. These limitations have directed research toward safer therapeutic alternatives with improved tolerability.

A growing number of studies emphasize the contribution of oxidative stress to the initiation and progression of melasma. Ultraviolet radiation promotes excessive production of reactive oxygen species, leading to melanocyte stimulation, enhanced tyrosinase activity, and increased melanin synthesis. In parallel, oxidative stress influences inflammatory mediators and dermal structural changes, further contributing to pigment persistence.

In this context, topical antioxidants have emerged as important modulators of melanogenesis. Rather than directly inhibiting melanocytes through cytotoxic mechanisms, antioxidants act by neutralizing free radicals, stabilizing cellular membranes, and regulating intracellular signaling pathways involved in pigment production. This indirect mechanism of action is associated with improved safety profiles compared to conventional depigmenting agents.

Among the antioxidants evaluated in the literature, silymarin has attracted particular attention due to its potent polyphenolic structure and multifunctional biological activity. Experimental and clinical data demonstrate that silymarin effectively reduces oxidative damage, suppresses tyrosinase activity, and limits ultraviolet-induced inflammatory responses. Clinical studies report meaningful reductions in melasma severity with minimal adverse reactions, supporting its suitability for long-term topical use.

Vitamins C and E also play significant roles in antioxidant-based therapy. Vitamin C contributes to depigmentation through reduction of oxidized melanin intermediates and inhibition of tyrosinase via copper chelation. Vitamin E primarily exerts protective effects on lipid membranes and enhances cutaneous antioxidant defense. When used in combination, these vitamins exhibit synergistic activity, resulting in enhanced photoprotection and stabilization of oxidative balance within the skin.

Despite promising outcomes, variability in formulation stability, skin penetration, and concentration significantly influences clinical efficacy. Differences among delivery systems and antioxidant combinations partially explain inconsistent results across studies. Nevertheless, accumulated evidence supports the inclusion of antioxidants as valuable components of comprehensive melasma management strategies.

Overall, current literature suggests that topical antioxidants represent a rational and safe therapeutic approach, particularly as adjunctive or maintenance therapy, and may contribute to improved long-term control of melasma with reduced risk of adverse effects.

4. DISCUSSIONS

The findings summarized in this review highlight the growing importance of antioxidant-based approaches in the management of melasma. As understanding of the disease has evolved, melasma is no longer considered solely a disorder of melanocyte hyperactivity, but rather a complex condition influenced by oxidative stress, inflammation, hormonal factors, and dermal alterations. This multifactorial nature explains the limited and often temporary success of monotherapy with conventional depigmenting agents.

Hydroquinone has long been regarded as the reference treatment for melasma; however, its use is associated with adverse reactions such as irritation, contact dermatitis, and post-inflammatory hyperpigmentation, particularly during prolonged therapy. These limitations have prompted increased interest in alternative agents capable of modulating melanogenesis through safer physiological mechanisms.

Topical antioxidants offer a rational therapeutic strategy by targeting oxidative pathways involved in pigment formation. Unlike cytotoxic depigmenting agents, antioxidants regulate melanin synthesis indirectly by neutralizing reactive oxygen species and reducing inflammatory signaling. This mechanism contributes to improved tolerability and supports their role in long-term treatment and maintenance regimens.

Among the reviewed compounds, silymarin appears particularly promising due to its combined antioxidant, anti-inflammatory, and anti-melanogenic activities. Clinical data indicate that topical silymarin formulations can reduce pigmentation severity with minimal adverse effects, making them suitable for patients with sensitive skin or those requiring prolonged therapy. Its plant-derived origin and favorable safety profile further support its potential clinical value.

Vitamins C and E remain well-established components of dermatological formulations. Although their depigmenting efficacy may be modest when used individually, their antioxidant and photoprotective properties provide significant supportive benefits. The synergistic interaction between these vitamins enhances oxidative defense and may contribute to improved clinical outcomes when incorporated into combination therapies.

Despite encouraging results, several limitations should be acknowledged. Variability in formulation stability, antioxidant concentration, and delivery systems may significantly influence therapeutic effectiveness. In addition, differences in study design, treatment duration, and outcome assessment limit direct comparison between clinical trials. These factors highlight the need for standardized formulations and well-designed randomized controlled studies.

Overall, antioxidant-based therapy represents a valuable component of a comprehensive melasma management strategy. While not intended to replace conventional treatments entirely, antioxidants may reduce reliance on aggressive depigmenting agents and improve long-term disease control. Future research should focus on optimizing formulation technologies, evaluating combination regimens, and conducting larger clinical studies to further clarify their therapeutic potential.

5. CONCLUSIONS

Melasma remains a challenging dermatological condition due to its complex pathogenesis, chronic course, and high tendency for recurrence. Increasing scientific evidence supports the significant role of oxidative stress in the regulation of melanogenesis, thereby providing a strong rationale for antioxidant-based therapeutic approaches.

This review demonstrates that topical antioxidants represent a safe and physiologically oriented strategy in the management of melasma. By modulating oxidative pathways and inflammatory mechanisms, antioxidants contribute to improved pigmentation control while minimizing the risk of adverse effects commonly associated with conventional depigmenting agents.

Among the reviewed compounds, silymarin emerges as a particularly promising antioxidant due to its multifunctional activity, favorable safety profile, and documented clinical efficacy. Vitamins C and E continue to play important supportive roles, especially when used in combination, enhancing antioxidant defense and photoprotective effects.

Although current evidence is encouraging, further well-designed clinical studies are required to establish optimal concentrations, formulation systems, and combination regimens. Future research should focus on standardized evaluation methods and long-term outcome assessment.

In conclusion, topical antioxidant therapy represents a valuable component of an integrated melasma management strategy and offers significant potential for safer and more sustainable long-term treatment.

REFERENCES

Altaei, T. (2012). The treatment of melasma by silymarin cream. *BMC Dermatology, 12*, 18.

Chen, J., Liu, Y., Zhao, Z., & Qiu, J. (2021). Oxidative stress in the skin: Impact and related protection. *International Journal of Cosmetic Science, 43*(5), 495–509.

Choo, S. J., Ryoo, I. J., Kim, Y. H., Xu, G. H., Kim, W. G., Kim, K. H., Moon, S. J., Son, E. D., Bae, K., & Yoo, I. D. (2009). Silymarin inhibits melanin synthesis in melanocyte cells. *Journal of Pharmacy and Pharmacology, 61*(5), 663–667.

Gupta, A. K., Gover, M. D., Nouri, K., & Taylor, S. (2006). The treatment of melasma: A review of clinical trials. *Journal of the American Academy of Dermatology, 55*(6), 1048–1065.

Handel, A. C., Miot, L. D. B., & Miot, H. A. (2014). Melasma: A clinical and epidemiological review. *Anais Brasileiros de Dermatologia, 89*(5), 771–782.

Honigman, A., & Rodrigues, M. (2023). Differential diagnosis of melasma and hyperpigmentation. *Dermatological Reviews, 4*(1), 30–37.

Lee, A. Y. (2014). An updated review of melasma pathogenesis. *Dermatologica Sinica, 32*(4), 233–239.

Nofal, A., Ibrahim, A. M., Nofal, E., Gamal, N., & Osman, S. (2019). Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study. *Journal of Cosmetic Dermatology, 18*(1), 263–270.

Rahimi, H., Mirnezami, M., Yazdabadi, A., & Hajihashemi, A. (2024). Evaluation of systemic oxidative stress in patients with melasma. *Journal of Cosmetic Dermatology, 23*(1), 284–288.

Rathee, P., Kumar, S., Kumar, D., Kumari, B., & Yadav, S. S. (2021). Skin hyperpigmentation and its treatment with herbs: An alternative method. *Future Journal of Pharmaceutical Sciences, 7*, 132.

Rigopoulos, D., Gregoriou, S., & Katsambas, A. (2007). Hyperpigmentation and melasma. *Journal of Cosmetic Dermatology, 6*(3), 195–202.

Sarkar, R., Devadasan, S., Choubey, V., & Goswami, B. (2020). Melatonin and oxidative stress in melasma: An unexplored territory; a prospective study. *International Journal of Dermatology, 59*(5), 572–575.

Thiele, J. J., Hsieh, S. N., & Ekanayake-Mudiyanselage, S. (2005). Vitamin E: Critical review of its current use in cosmetic and clinical dermatology. *Dermatologic Surgery, 31*(7 Pt 2), 805–813.

Victor, F. C., Gelber, J., & Rao, B. (2004). Melasma: A review. *Journal of Cutaneous Medicine and Surgery, 8*(2), 97–102.

Zheng, H., Pei, Q., & Yao, M. (2024). Understanding melasma: From pathogenesis to innovative treatments. *Dermatologic Therapy*, 2206130.